Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2021 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, February 2021
Slide 1: Agilent Technologies Q1'21 Results Presentation
Agilent Technologies Q1’21 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q1'21
Agilent Results Q1'21 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1'21 Financial Metrics Q1’21 Highlights • Revenues: $1.55B, +11.3% y/y • Growth: Broad based growth in base-business across core(1)(2),+14.1% reported (+2.8% FX). segments, regions and most m
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q1 core revenue performance reflected strong Instrumentation and Informatics for Analytical Laboratories calendar year-end spending and generally improving conditions across geographies led by growth in the Food and Pharma markets. Cell Analysis, Liquid
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory Consumables and Services • Double-digit revenue performance in Q1 reflected continued improving lab operating environments. Growth was broad across all markets and geographies. • ACG grew in the mid-twenties in China. Excellent execution continues
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and Nucleic Acid Manufacturing • Q1 core revenue growth driven by strong Pharma market, including continued strong ramp in NASD. • Announced FDA approval for the expanded NGS Target Enrichment use of PD-L1 IHC 22C3 pharmDx as an aid in identi
Slide 7: Growth in a $58B Market – Q1'21 Results by End Market
Growth in a $58B Market – Q1'21 Results by End Market Growth Across Most Markets Led by Food & Pharma Analytical Laboratory End Markets Q1'21 revenues: +12% y/y on core(2) basis Pharma & Biotech: Up 20%. Buoyed by year-end spending with strength across geographies. Healthy growth in both large a
Slide 8: Q2'21 and FY21 Guidance and Forward-looking Considerations
Q2’21 and FY21 Guidance and Forward-looking Considerations Based on January 31, 2021 Exchange Rates Q2’21 Guidance (1) FY21 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,370 $1,390 Net Revenue ($M) $5,825 $5,900 Y/Y Core Revenue Growth (2) 7% 9% Y/Y Core Revenue Growth (2) 6.5%